Biodexa Pharmaceticals Stock Today
| BDRX Stock | 3.45 0.10 2.82% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Biodexa Pharmaceticals is trading at 3.45 as of the 25th of February 2025; that is 2.82 percent down since the beginning of the trading day. The stock's open price was 3.55. Biodexa Pharmaceticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 25th of February 2025. Click here to learn more.
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Biodexa Stock Highlights
| CFO, CEO | Stephen Stamp |
| Old Name | Biodexa Pharmaceticals |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Biodexa Pharmaceticals (BDRX) is traded on NASDAQ Exchange in USA. It is located in 1 Caspian Point, Cardiff, United Kingdom, CF10 4DQ and employs 21 people. Biodexa Pharmaceticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.37 M. Biodexa Pharmaceticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 668.59 K outstanding shares of which 3.24 K shares are currently shorted by private and institutional investors with about 0.23 trading days to cover.
Biodexa Pharmaceticals generates negative cash flow from operations
Check Biodexa Pharmaceticals Probability Of Bankruptcy
Ownership AllocationBiodexa Pharmaceticals shows 8.82 percent of its outstanding shares held by insiders and 29.85 percent owned by other corporate entities.
Check Biodexa Ownership Details
Biodexa Pharmaceticals Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Biodexa Pharmaceticals market risk premium is the additional return an investor will receive from holding Biodexa Pharmaceticals long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.38) | |||
| Total Risk Alpha | (0.42) | |||
| Treynor Ratio | (0.61) |
Biodexa Stock Against Markets
Biodexa Pharmaceticals Corporate Management
| Nicola Tuckwell | VP Operations | Profile | |
| Dmitry MD | Chief Officer | Profile | |
| Daniel MBA | Vice Technology | Profile | |
| Fiona Sharp | Group Controller | Profile | |
| Steve Ellul | Chief Officer | Profile | |
| CPI FACOG | Chief Officer | Profile |
Additional Tools for Biodexa Stock Analysis
When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.